The Latest Medical News

A Summary of The Latest Medical News: ### Breakthrough in Depression Treatment: A Single Dose of DMT Shows Promise A phase 2 clinical trial has revealed that a single dose of the psychedelic drug dimethyltryptamine (DMT), combined with psychotherapy, can rapidly and significantly reduce symptoms of major depressive disorder (MDD) in patients who failed prior treatments.[1][2][3] **The Study Design** Researchers from Imperial College London and Helus Pharma (using SPL026, a DMT formulation) conducted a double-blind, placebo-controlled phase IIa trial with 34 adults suffering moderate-to-severe MDD.[1][2][3] Participants had tried at least two previous treatments without success, including antidepressants or therapy.[2][3] In the first stage, 17 received a 21.5mg intravenous DMT dose over about 10 minutes, while 17 got an active placebo; therapists provided silent support during the brief psychedelic effects.[1][3] Two weeks later, in an open-label phase, all could receive DMT.[1][2] **Rapid and Lasting Results** One week post-dose, DMT patients saw a 10.8-point drop in Montgomery-Åsberg Depression Rating Scale (MADRS) scores versus placebo—a clinically meaningful reduction.[1][2][3] At two weeks, the gap held at 7.4 points lower for DMT.[2][3] Effects persisted up to three months for many, and six months for some; a single dose matched two doses in efficacy.[1][2][3] **Why DMT Stands Out** Unlike longer-acting psychedelics like psilocybin or LSD (hours-long effects), intravenous DMT's psychedelic peak lasts just minutes with a five-minute half-life, making it clinic-friendly and potentially cheaper.[1][3] The trial linked benefits to the intensity of the psychedelic experience.[3] **Safety Profile** Treatment was well-tolerated: mild side effects included nausea, transient anxiety, injection-site pain, and brief rises in heart rate/blood pressure—no serious adverse events or suicidal ideation changes.[1][3] **Caveats and Next Steps** Blinding may have been compromised by obvious psychedelic effects; small sample size (34) limits generalizability.[1] Larger, longer trials comparing DMT to existing therapies are needed for efficacy, safety, and cost data.[1][3] Results published in *Nature Medicine*.[1][3] **A New Hope for Treatment-Resistant Depression** This ayahuasca-derived compound offers a quick, potent option for hard-to-treat depression, building on psychedelics' momentum—watch for phase 3 advancements.[1][3] Help with your insurance? https://tally.so/r/n012P9